CNS Pharmaceuticals (CNSP) Reports $2.5M Q3 Net Loss, Seeks Deal by Year-End
CNS Pharmaceuticals reported a Q3 2026 net loss of approximately $2.5M, versus $3.2M in Q3 2025. It had $17.2M in cash at September 30, 2026, and aims to complete its first acquisition or licensing transaction by year-end.Material DetailsContext by AI AnalystThe company is pursuing a pipeline-build…